Candriam SCA’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-35,380
| Closed | -$459K | – | 715 |
|
|
2023
Q4 | $459K | Sell |
35,380
-40,666
| -53% | -$548K | ﹤0.01% | 665 |
|
|
2023
Q3 | $1.53M | Sell |
76,046
-19,667
| -21% | -$441K | 0.01% | 486 |
|
|
2023
Q2 | $2.57M | Sell |
95,713
-6,622
| -6% | -$285K | 0.02% | 452 |
|
|
2023
Q1 | $5.5M | Hold |
102,335
| – | – | 0.04% | 343 |
|
|
2022
Q4 | $5.22M | Buy |
102,335
+13,333
| +15% | +$924K | 0.04% | 370 |
|
|
2022
Q3 | $7.29M | Buy |
89,002
+6,620
| +8% | +$494K | 0.05% | 324 |
|
|
2022
Q2 | $5.57M | Sell |
82,382
-6,620
| -7% | -$607K | 0.05% | 312 |
|
|
2022
Q1 | $9.84M | Buy |
89,002
+30,491
| +52% | +$3.8M | 0.07% | 260 |
|
|
2021
Q4 | $5.64M | Buy |
58,511
+10,666
| +22% | +$1.06M | 0.04% | 338 |
|
|
2021
Q3 | $4.18M | Hold |
47,845
| – | – | 0.03% | 429 |
|
|
2021
Q2 | $7.41M | Sell |
47,845
-15,593
| -25% | -$2.26M | 0.05% | 329 |
|
|
2021
Q1 | $14.1M | Sell |
63,438
-1
| -0% | -$211 | 0.12% | 192 |
|
|
2020
Q4 | $14.7M | Buy |
63,439
+28,548
| +82% | +$6.62M | 0.12% | 194 |
|
|
2020
Q3 | $7.64M | Buy |
34,891
+17,593
| +102% | +$4.3M | 0.07% | 276 |
|
|
2020
Q2 | $4.91M | Sell |
17,298
-39,060
| -69% | -$11.6M | 0.05% | 337 |
|
|
2020
Q1 | $15.8M | Buy |
56,358
+2
| +0% | +$552 | 0.18% | 135 |
|
|
2019
Q4 | $16.2M | Sell |
56,356
-15,126
| -21% | -$3.28M | 0.17% | 135 |
|
|
2019
Q3 | $10.3M | Sell |
71,482
-58,303
| -45% | -$7.9M | 0.14% | 178 |
|
|
2019
Q2 | $11.6M | Buy |
129,785
+5,333
| +4% | +$428K | 0.14% | 165 |
|
|
2019
Q1 | $10.9M | Buy |
124,452
+4,949
| +4% | +$549K | 0.14% | 173 |
|
|
2018
Q4 | $16.8M | Buy |
119,503
+47,136
| +65% | +$7.95M | 0.26% | 86 |
|
|
2018
Q3 | $18.5M | Buy |
72,367
+39,567
| +121% | +$10.9M | 0.25% | 98 |
|
|
2018
Q2 | $8.36M | Buy |
32,800
+18,133
| +124% | +$4.49M | 0.13% | 196 |
|
|
2018
Q1 | $2.95M | Sell |
14,667
-12,200
| -45% | -$2.43M | 0.05% | 392 |
|
|
2017
Q4 | $3.87M | Sell |
26,867
-7,133
| -21% | -$1.15M | 0.07% | 321 |
|
|
2017
Q3 | $5.6M | Buy |
34,000
+4,800
| +16% | +$688K | 0.1% | 242 |
|
|
2017
Q2 | $3.96M | Buy |
29,200
+17,733
| +155% | +$2.62M | 0.07% | 313 |
|
|
2017
Q1 | $2.21M | Sell |
11,467
-14,533
| -56% | -$2.33M | 0.04% | 425 |
|
|
2016
Q4 | $3.67M | Buy |
26,000
+8,000
| +44% | +$1.08M | 0.08% | 260 |
|
|
2016
Q3 | $2.63M | Buy |
18,000
+7,333
| +69% | +$881K | 0.06% | 303 |
|
|
2016
Q2 | $1.07M | Sell |
10,667
-1,800
| -14% | -$234K | 0.03% | 421 |
|
|
2016
Q1 | $1.66M | Sell |
12,467
-273
| -2% | -$30.1K | 0.04% | 350 |
|
|
2015
Q4 | $2.53M | Buy |
12,740
+2,000
| +19% | +$433K | 0.07% | 266 |
|
|
2015
Q3 | $1.7M | Buy |
10,740
+1,873
| +21% | +$501K | 0.04% | 364 |
|
|
2015
Q2 | $3.62M | Sell |
8,867
-9,066
| -51% | -$3.92M | 0.08% | 283 |
|
|
2015
Q1 | $8.24M | Sell |
17,933
-1,934
| -10% | -$834K | 0.17% | 173 |
|
|
2014
Q4 | $11.2M | Buy |
+19,867
| New | +$11.3M | 0.23% | 132 |
|
Other funds holding KPTI
APM
PAI
EP
Candriam SCA's KPTI Position: Q1 2024 in Review
Candriam SCA sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 35,380 shares — an estimated $459K sold.
Candriam SCA first reported a position in KPTI in Q4 2014 and held it in 37 quarters. The position peaked at $18.5M in Q3 2018. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.
- Candriam SCA reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
- Candriam SCA sold 35,380 Karyopharm Therapeutics shares in Q1 2024, an estimated $459K.
- Candriam SCA first reported a position in Karyopharm Therapeutics in Q4 2014 and held it in 37 quarters.
- Candriam SCA's Karyopharm Therapeutics position peaked at $18.5M in Q3 2018.
- 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.
Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.